Novavax, Sanofi vaccine licensing deal

Novavax shares soar on license deal with Sanofi at lofty valuation

Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market capitalization.

Seeking Alpha on MSN · 2d

Novavax top investor ends proxy fight after Sanofi deal

Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the COVID-19 vaccine maker struck a licensing agreement with French pharma giant Sanofi (SNY).

Forbes on MSN · 13d

Novavax Shares Surge Over 130% After $1.4 Billion Covid Shot Deal With Sanofi

The biotech company said it would develop a combination Covid and flu shot with Sanofi as part of a billion-dollar deal.

Benefits Pro11d

Novavax strikes $1.2B deal with Sanofi to develop COVID-flu combo vaccine

With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race ...

Seeking Alpha on MSN13d

Novavax hits 52-week high as Sanofi deal brings upgrades (update)

Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice ...

NBC Washington11d

Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results